Top

Clinical Research in Cardiology

Published in:

01-05-2008 | ORIGINAL PAPER

Usefulness of myocardial performance index and biochemical markers for early detection of anthracycline-induced cardiotoxicity in adults

Authors: Fotiní Dodos, MD, Teresa Halbsguth, MD, Erland Erdmann, MD, Uta C. Hoppe, MD

Published in: Clinical Research in Cardiology | Issue 5/2008

Abstract

Background

Anthracycline therapy is limited by cardiotoxicity. Currently no diagnostic parameter is available allowing ubiquitous and reliable detection of preclinical anthracycline cardiomyopathy and prediction of prognosis.

Patients and methods

In 100 consecutive patients receiving anthracycline-based chemotherapy serial measurements of left ventricular systolic and diastolic function, Tei index (a Doppler echocardiographic parameter of global ventricular function), cardiac troponin T (cTnT) and NT-probrain natriuretic peptides (BNP) at baseline and during 1-year follow-up were performed.

Results

Mean ejection fraction (LVEF) significantly decreased immediately after completion of anthracycline therapy (mean dose 226.1 ± 8.3 mg/m²) und further declined during follow-up (65.9 ± 0.6% Vs. 61.6 ± 0.7%; P < 0.001), while mean E/A ratio decreased after 6 months (P = 0.05). No patient presented with cardiac symptoms. The Tei index increased after therapy in the majority of patients (78.8%) compared with pre-therapy values indicating myocardial alteration in more patients than previously recognized. cTnT levels did not exceed the upper limit of the normal range in any patient. Seven patients had low-level elevations of cTnT. Only one of these patients developed a concomitant decrease in LVEF. Mean N-terminal-pro-BNP (NT-proBNP) levels did not significantly change after anthracycline administration. However, in 13 patients (15.3%) a marked, transient increase of NT-proBNP was obtained after the first anthracycline cycle without cardiac dysfunction presumably due to altered cardiac loading conditions during chemotherapy.

Conclusion

Low to moderate doses of anthracyclines resulted in subclinical myocardial alteration in more patients than so far noticed. Clinical implications of increased Tei index remain to be determined in long-term. Our results do not support that assessment of cTnT or BNP levels may safely replace serial echocardiographic evaluation of systolic and diastolic function for the monitoring of anthracycline cardiotoxicity.

Auner HW, Tinchon C, Linkesch W, Tiran A, Quehenberger F, Link H, Sill H (2003) Prolonged monitoring of troponin T for the detection of anthracycline cardiotoxicity in adults with hematological malignancies. Ann Hematol 82:218–222PubMed

Belham M, Kruger A, Pritchard C (2006) The Tei index identifies a differential effect on left and right ventricular function with low-dose anthracycline chemotherapy. J Am Soc Echocardiogr 19:206–210PubMedCrossRef

Brenner JS, Dolmetsch RE (2007) TrpC3 regulates hypertrophy-associated gene expression without affecting myocyte beating or cell size. PLoS ONE 2:e802PubMedCrossRef

Cardinale D, Sandri MT, Martinoni A, Borghini E, Civelli M, Lamantia G, Cinieri S, Martinelli G, Fiorentini C, Cipolla CM (2002) Myocardial injury revealed by plasma troponin I in breast cancer treated with high-dose chemotherapy. Ann Oncol 13:710–715PubMedCrossRef

Cardinale D, Sandri MT, Martinoni A, Tricca A, Civelli M, Lamantia G, Cinieri S, Martinelli G, Cipolla CM, Fiorentini C (2000) Left ventricular dysfunction predicted by early troponin I release after high-dose chemotherapy. J Am Coll Cardiol 36:517–522PubMedCrossRef

Daugaard G, Lassen U, Bie P, Pedersen EB, Jensen KT, Abildgaard U, Hesse B, Kjaer A (2005) Natriuretic peptides in the monitoring of anthracycline induced reduction in left ventricular ejection fraction. Eur J Heart Fail 7:87–93PubMedCrossRef

Dujardin KS, Tei C, Yeo TC, Hodge DO, Rossi A, Seward JB (1998) Prognostic value of a Doppler index combining systolic and diastolic performance in idiopathic-dilated cardiomyopathy. Am J Cardiol 82:1071–1076PubMedCrossRef

Efferth T, Giaisi M, Merling A, Krammer PH, Li-Weber M (2007) Artesunate induces ROS-mediated apoptosis in doxorubicin-resistant T leukemia cells. PLoS ONE 2:e693PubMedCrossRef

Eidem BW, Sapp BG, Suarez CR, Cetta F (2001) Usefulness of the myocardial performance index for early detection of anthracycline-induced cardiotoxicity in children. Am J Cardiol 87:1120–1122, A1129PubMedCrossRef

10.

Ewer MS, Ali MK, Gibbs HR, Swafford J, Graff KL, Cangir A, Jaffe N, Thapar MK (1994) Cardiac diastolic function in pediatric patients receiving doxorubicin. Acta Oncol 33:645–649PubMedCrossRef

11.

Herman EH, Zhang J, Lipshultz SE, Rifai N, Chadwick D, Takeda K, Yu ZX, Ferrans VJ (1999) Correlation between serum levels of cardiac troponin-T and the severity of the chronic cardiomyopathy induced by doxorubicin. J Clin Oncol 17:2237–2243PubMed

12.

Hullin R, Matthes J, von Vietinghoff S, Bodi I, Rubio M, D’Souza K, Friedrich Khan I, Rottlander D, Hoppe UC, Mohacsi P, Schmitteckert E, Gilsbach R, Bunemann M, Hein L, Schwartz A, Herzig S (2007) Increased expression of the auxiliary beta2-subunit of ventricular L-type Ca²⁺ channels leads to single-channel activity characteristic of heart failure. PLoS ONE 2:e292PubMedCrossRef

13.

Ishii M, Tsutsumi T, Himeno W, Eto G, Furui J, Hashino K, Sugahara Y, Muta H, Akagi T, Ando A, Eguchi H, Kato H (2000) Sequential evaluation of left ventricular myocardial performance in children after anthracycline therapy. Am J Cardiol 86:1279–1281, A1279PubMedCrossRef

14.

Keefe DL (2001) Anthracycline-induced cardiomyopathy. Semin Oncol 28(Suppl 12):2–7PubMed

15.

Kilickap S, Barista I, Akgul E, Aytemir K, Aksoyek S, Aksoy S, Celik I, Kes S, Tekuzman G (2005) cTnT can be a useful marker for early detection of anthracycline cardiotoxicity. Ann Oncol 16:798–804PubMedCrossRef

16.

Kremer LC, Bastiaansen BA, Offringa M, Lam J, van Straalen JP, de Winter RJ, Voute PA (2002) Troponin T in the first 24 hours after the administration of chemotherapy and the detection of myocardial damage in children. Eur J Cancer 38:686–689PubMedCrossRef

17.

Kurz K, Voelker R, Zdunek D, Wergeland R, Hess G, Ivandic B, Katus H, Giannitsis E (2007) Effect of stress-induced reversible ischemia on serum concentrations of ischemia-modified albumin, natriuretic peptides and placental growth factor. Clin Res Cardiol 96:152–159PubMedCrossRef

18.

Latini R, Masson S, Anand IS, Missov E, Carlson M, Vago T, Angelici L, Barlera S, Parrinello G, Maggioni AP, Tognoni G, Cohn JN (2007) Prognostic value of very low plasma concentrations of troponin T in patients with stable chronic heart failure. Circulation 116:1242–1249PubMedCrossRef

19.

Lee BH, Goodenday LS, Muswick GJ, Yasnoff WA, Leighton RF, Skeel RT (1987) Alterations in left ventricular diastolic function with doxorubicin therapy. J Am Coll Cardiol 9:184–188PubMed

20.

Lipshultz SE, Rifai N, Dalton VM, Levy DE, Silverman LB, Lipsitz SR, Colan SD, Asselin BL, Barr RD, Clavell LA, Hurwitz CA, Moghrabi A, Samson Y, Schorin MA, Gelber RD, Sallan SE (2004) The effect of dexrazoxane on myocardial injury in doxorubicin-treated children with acute lymphoblastic leukemia. N Engl J Med 351:145–153PubMedCrossRef

21.

Lipshultz SE, Rifai N, Sallan SE, Lipsitz SR, Dalton V, Sacks DB, Ottlinger ME (1997) Predictive value of cardiac troponin T in pediatric patients at risk for myocardial injury. Circulation 96:2641–2648PubMed

22.

Marchandise B, Schroeder E, Bosly A, Doyen C, Weynants P, Kremer R, Pouleur H (1989) Early detection of doxorubicin cardiotoxicity: interest of Doppler echocardiographic analysis of left ventricular filling dynamics. Am Heart J 118:92–98PubMedCrossRef

23.

Mason JW, Bristow MR, Billingham ME, Daniels JR (1978) Invasive and noninvasive methods of assessing adriamycin cardiotoxic effects in man: superiority of histopathologic assessment using endomyocardial biopsy. Cancer Treat Rep 62:857–864PubMed

24.

Meinardi MT, van Veldhuisen DJ, Gietema JA, Dolsma WV, Boomsma F, van den Berg MP, Volkers C, Haaksma J, de Vries EG, Sleijfer DT, van der Graaf WT (2001) Prospective evaluation of early cardiac damage induced by epirubicin-containing adjuvant chemotherapy and locoregional radiotherapy in breast cancer patients. J Clin Oncol 19:2746–2753PubMed

25.

Nousiainen T, Jantunen E, Vanninen E, Hartikainen J (2002) Early decline in left ventricular ejection fraction predicts doxorubicin cardiotoxicity in lymphoma patients. Br J Cancer 86:1697–1700PubMedCrossRef

26.

Pai VB, Nahata MC (2000) Cardiotoxicity of chemotherapeutic agents: incidence, treatment and prevention. Drug Saf 22:263–302PubMedCrossRef

27.

Ribeiro I, Kawakami Y, Buscher D, Raya A, Rodriguez-Leon J, Morita M, Rodriguez Esteban C, Izpisua Belmonte JC (2007) Tbx2 and Tbx3 regulate the dynamics of cell proliferation during heart remodeling. PLoS ONE 2:e398PubMedCrossRef

28.

Roth HJ, Leithauser RM, Doppelmayr H, Doppelmayr M, Finkernagel H, von Duvillard SP, Korff S, Katus HA, Giannitsis E, Beneke R (2007) Cardiospecificity of the 3rd generation cardiac troponin T assay during and after a 216 km ultra-endurance marathon run in death valley. Clin Res Cardiol 96:359–364PubMedCrossRef

29.

Sahn DJ, DeMaria A, Kisslo J, Weyman A (1978) Recommendations regarding quantitation in M-mode echocardiography: results of a survey of echocardiographic measurements. Circulation 58:1072–1083PubMed

30.

Sato T, Harada K, Tamura M, Watanabe A, Ishii M, Takada G (2001) Cardiorespiratory exercise capacity and its relation to a new Doppler index in children previously treated with anthracycline. J Am Soc Echocardiogr 14:256–263PubMedCrossRef

31.

Scharhag J, Herrmann M, Weissinger M, Herrmann W, Kindermann W (2007) N-terminal B-type natriuretic peptide concentrations are similarly increased by 30 minutes of moderate and brisk walking in patients with coronary artery disease. Clin Res Cardiol 96:218–226PubMedCrossRef

32.

Shan K, Lincoff AM, Young JB (1996) Anthracycline-induced cardiotoxicity. Ann Intern Med 125:47–58PubMed

33.

Snowden JA, Hill GR, Hunt P, Carnoutsos S, Spearing RL, Espiner E, Hart DN (2000) Assessment of cardiotoxicity during haemopoietic stem cell transplantation with plasma brain natriuretic peptide. Bone Marrow Transplant 26:309–313PubMedCrossRef

34.

Steinherz LJ, Steinherz PG, Tan CT, Heller G, Murphy ML (1991) Cardiac toxicity 4 to 20 years after completing anthracycline therapy. JAMA 266:1672–1677PubMedCrossRef

35.

Stoddard MF, Seeger J, Liddell NE, Hadley TJ, Sullivan DM, Kupersmith J (1992) Prolongation of isovolumetric relaxation time as assessed by Doppler echocardiography predicts doxorubicin-induced systolic dysfunction in humans. J Am Coll Cardiol 20:62–69PubMedCrossRef

36.

Suzuki T, Hayashi D, Yamazaki T, Mizuno T, Kanda Y, Komuro I, Kurabayashi M, Yamaoki K, Mitani K, Hirai H, Nagai R, Yazaki Y (1998) Elevated B-type natriuretic peptide levels after anthracycline administration. Am Heart J 136:362–363PubMedCrossRef

37.

Swain SM, Whaley FS, Ewer MS (2003) Congestive heart failure in patients treated with doxorubicin: a retrospective analysis of three trials. Cancer 97:2869–2879PubMedCrossRef

38.

Tei C (1995) New non-invasive index for combined systolic and diastolic ventricular function. J Cardiol 26:135–136PubMed

39.

Tei C, Nishimura RA, Seward JB, Tajik AJ (1997) Noninvasive Doppler-derived myocardial performance index: correlation with simultaneous measurements of cardiac catheterization measurements. Am J Soc Echocardiogr 10:169–178CrossRef

40.

Tikanoja T, Riikonen P, Perkkio M, Helenius T (1998) Serum N-terminal atrial natriuretic peptide (NT-ANP) in the cardiac follow-up in children with cancer. Med Pediatr Oncol 31:73–78PubMedCrossRef

41.

Tjeerdsma G, Meinardi MT, van Der Graaf WT, van Den Berg MP, Mulder NH, Crijns HJ, de Vries EG, van Veldhuisen DJ (1999) Early detection of anthracycline induced cardiotoxicity in asymptomatic patients with normal left ventricular systolic function: autonomic versus echocardiographic variables. Heart 81:419–423PubMed

42.

Weber M, Kleine C, Keil E, Rau M, Berkowitsch A, Elsaesser A, Mitrovic V, Hamm C (2006) Release pattern of N-terminal pro B-type natriuretic peptide (NT-proBNP) in acute coronary syndromes. Clin Res Cardiol 95:270–280PubMedCrossRef

43.

Yeh ET, Tong AT, Lenihan DJ, Yusuf SW, Swafford J, Champion C, Durand JB, Gibbs H, Zafarmand AA, Ewer MS (2004) Cardiovascular complications of cancer therapy: diagnosis, pathogenesis, and management. Circulation 109:3122–3131PubMedCrossRef

44.

Yeo TC, Dujardin KS, Tei C, Mahoney DW, McGoon MD, Seward JB (1998) Value of a Doppler-derived index combining systolic and diastolic time intervals in predicting outcome in primary pulmonary hypertension. Am J Cardiol 81:1157–1161PubMedCrossRef

Title: Usefulness of myocardial performance index and biochemical markers for early detection of anthracycline-induced cardiotoxicity in adults
Authors: Fotiní Dodos, MD
Teresa Halbsguth, MD
Erland Erdmann, MD
Uta C. Hoppe, MD
Publication date: 01-05-2008
Publisher: D. Steinkopff-Verlag
Published in: Clinical Research in Cardiology / Issue 5/2008
Print ISSN: 1861-0684
Electronic ISSN: 1861-0692
DOI: https://doi.org/10.1007/s00392-007-0633-6

ACC 2024 Congress Coverage

Heart Failure Video

At a glance: The ONWARDS insulin icodec trials

Springer Medicine

Usefulness of myocardial performance index and biochemical markers for early detection of anthracycline-induced cardiotoxicity in adults

Abstract

Background

Patients and methods

Results

Conclusion

ACC 2024 Congress Coverage

Year in Review: Heart failure and cardiomyopathies

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

Incentivised to exercise

New intervention for STEMI-related cardiogenic shock

» View more highlights on the ACC 2024 congress hub page

At a glance: The ONWARDS insulin icodec trials

Springer Medicine

Abstract

Background

Patients and methods

Results

Conclusion

Please log in to get access to this content

Other articles of this Issue 5/2008

Revival of an old method with new techniques: balloon aortic valvuloplasty of the calcified aortic stenosis in the elderly

Elevated B-type natriuretic peptide levels in patients with nonischemic cardiomyopathy predict occurrence of arrhythmic events

Therapy effects of green tea in a patient with systemic light-chain amyloidosis

Review on balloon aortic valvuloplasty: a surgeon’s perspective in 2008

Allopurinol improves endothelial function and reduces oxidant-inflammatory enzyme of myeloperoxidase in metabolic syndrome

Antithrombotic triple therapy in a patient with multiple thrombi, subacute myocardial infarction and coronary stent implantation

ACC 2024 Congress Coverage

Year in Review: Heart failure and cardiomyopathies

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

Incentivised to exercise

New intervention for STEMI-related cardiogenic shock

» View more highlights on the ACC 2024 congress hub page